

United States Patent and Trademark Office

5

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

_				** T	•
	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	10/625,820	07/23/2003	Jonathan Maynes	CEN0017-01	7804
		7590 09/24/2007 Richard B. Taylor James L. Cordek		EXAMINER	
	James L. Corde			PADEN, CAROLYN A	
	Solae, LLC P.O. Box 88940)		ART UNIT	PAPER NUMBER
	St. Louis, MO	53188		1761	
				MAIL DATE	DELIVERY MODE
				09/24/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

· · · · · · · · · · · · · · · · · · ·		Application No.	Applicant(s)				
		10/625,820	MAYNES, JONATHAN				
	Office Action Summary	Examiner	Art Unit				
		Carolyn A. Paden	1761				
Period fo	The MAILING DATE of this communication apport Reply	ears on the cover sheet w	ith the correspondence address				
WHI(- Exte after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNI 36(a). In no event, however, may a vill apply and will expire SIX (6) MOI , cause the application to become A	CATION. reply be timely filed NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed on 23 Au	ugust 2007.					
2a) <u></u> □	This action is FINAL . 2b)⊠ This	action is non-final.					
3) 🗌	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5)□ 6)⊠ 7)⊠	Claim(s) <u>1,2,4,8-18 and 20-22</u> is/are pending ir 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) <u>1,2,4,8,15-18,21 and 22</u> is/are rejecte Claim(s) <u>9-14 and 20</u> is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.					
Applicat	ion Papers						
9)	The specification is objected to by the Examine	r.					
10)	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the	. ,	• • • • • • • • • • • • • • • • • • • •				
11)	Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	· · · · · · · · · · · · · · · · · · ·					
Priority (under 35 U.S.C. § 119						
a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau See the attached detailed Office action for a list of	s have been received. s have been received in A rity documents have been ı (PCT Rule 17.2(a)).	application No received in this National Stage				
Attachmen	e of References Cited (PTO-892)	4) ☐ Interview	Summary (PTO-413)				
2) Notice 3) Information	te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	Paper No(s)/Mail Date nformal Patent Application				

Art Unit: 1761

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1 & 2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Umeda (5,833,858) as further evidenced by Merck Index for reasons of record.

Applicant argues that Umeda is directed to acidic phospholipids that do not contain phospholipids. This has been considered but is not persuasive because the rejection is based upon the composition of defatted soybean lecithin of Table 2. Applicant urges that the sugar content of the composition is less than 1%. This has been considered but is not persuasive because the components of Table 2 are substantially phospholipids and would not be expected to contain sugar.

Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Umeda as further evidenced by Merck Index as

Art Unit: 1761

applied to claims 1-2 above, and further in view of Losch for reasons of record used in rejecting claims 1, 2 and 4 in the last office action.

Applicant argues that Losch has a different composition than Umeda. This has been considered but is not persuasive. Losch is relied upon to show that granulated lecithin is known in the art. The fact that the components in Losch are different does not take away the teaching of granulated lecithin that is relied upon in the reference.

Claims 8, 15-18, 21 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pardum in view of Umeda as further evidenced by Merck for reasons of record.

Applicant argues that Pardum prepares a phosphatide with less than 1% sugar. No difference is seen between the sugar content of Pardum and the sugar content of the claims. Applicant argues that the Pardum resin in example 3 is not applicants' invention. The Pardum residue is made by the same basic process as that described in the claims. The phosphatidyl choline content of the lecithin residue falls within the range of the claims. The Pardum process provides for up to 30% water in the alcohol for extraction. So even though the amount of phosphatidyl ethanolamine and phosphatidyl inositol is different from that of the claims, one of ordinary skill in the art would

Art Unit: 1761

expect the lecithin composition to fall within the range of the claims because the process is an obvious variant of the Pardum process. No unobvious or unexpected result is seen between the extraction process of Pardum and the extraction process of the claims.

Claims 9-14 and 20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carolyn A Paden whose telephone number is (571) 272-1403. The examiner can normally be reached on Monday to Friday from 7 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Keith Hendricks, can be reached on (571) 272-1401 or by dialing 571-272-1700. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be

Art Unit: 1761

217-9197 (toll-free).

obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-

CAROLYN PADEN 9 - 19-0

Page 5

PRIMARY EXAMINER 176